Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Gemcitabine 54130-nm albumin-bound paclitaxel 29Magnetic Resonance Spectroscopy 21Taxes 18Fluorouracil 18Specimen Handling 17Oxaliplatin 17Leucovorin 17Drug Therapy 17Albumin-Bound Paclitaxel 17Irinotecan 14pembrolizumab 13Cyclophosphamide 11Blood Specimen Collection 11Biopsy 11fludarabine 10Radiosurgery 9irinotecan sucrosofate 8folfirinox 6Magnetic Resonance Imaging 6Cetuximab 6Bevacizumab 6dehydroftorafur 5Surveys and Questionnaires 5Nivolumab 5Endoscopic Ultrasound-Guided Fine Needle Aspiration 5sintilimab 4olaparib 4balstilimab 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Neoplasms × azeliragon × Clear all
NCT05766748 2024-06-14

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

Cantex Pharmaceuticals

Phase 1/2 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡